MenuМеню
  • Home
  • About Us
  • Medicines
  • Partnering
  • Professionals
  • Responsibility
  • News & Media
  • Careers
  • Investors
  • English
  • Bulgarian

News and Media

  • Financial News
  • News
  • Opinion Pieces
  • Press Releases
  • October 5, 2020

    Prof. Dr. Rasho Rashkov: Rheumatic patients are more protected than COVID-19 … especially those who take hydroxychloroquine

    Patients with rheumatic disease are less likely to suffer from coronavirus, especially those taking hydroxychloroquine. That is why their therapy should not be interrupted during the pandemic, says rheumatologist Prof. Rasho Rashkov and clarifies that he and his colleagues have many years of experience in the treatment with hydroxychloroquine, as well as treatment of some […]

  • October 3, 2020

    Tchaikapharma remains the most expensive company

    Tchaikapharma High Quality Medicines Inc. remains the most expensive Bulgarian company on the Bulgarian Stock Exchange. After the market capitalization of the pharmaceutical company exceeded BGN 1 billion at the end of June, in July, August and September it added more value to its stock market valuation.   The full article is available here in […]

  • July 13, 2020

    There is a company on the BSE with a value of over one billion leva – this is Tchaikapharma!

    There is a company on the Bulgarian Stock Exchange with a value of over a billion leva, according to data in the bulletin of the stock exchange operator for the second quarter. This is Tchaikapharma High Quality Medicines. By the end of June, the stock exchange players estimated the pharmaceutical company at BGN 1,027,500,000.   […]

  • July 7, 2020

    Gen. Mutafchiyski: Hydroxychloroquine has not been rejected for treatment

    Briefing at the Ministry of health

  • June 30, 2020

    Tchaikapharma International Press Center informs: Global COVID-19 prevention trial of hydroxychloroquine to resume

    Global COVID-19 prevention trial of hydroxychloroquine to resume   LONDON (Reuters) – A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators.   The Medicines and Healthcare Products Regulatory Agency (MHRA) took its decision on what is known […]

  1. Previous
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5
  7. 6
  8. 7
  9. 8
  10. 9
  11. 10
  12. ...
  13. 36
  14. Next
Copyright © 2010-2025 Tchaikapharma Inc.
  • Contact Us